Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LB 101 - Centessa Pharmaceuticals

Next Previous
X
Search
Drug Profile

LB 101 - Centessa Pharmaceuticals

Alternative Names: LB-101 - Centessa Pharmaceuticals; LB1 - Centessa Pharmaceuticals

Latest Information Update: 04 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lockbody
  • Developer Centessa Pharmaceuticals; Lockbody
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 28 Mar 2023 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable, Monotherapy) in USA (IV) (NCT05821777)
  • 26 Jan 2023 The US FDA approves IND application for LB 101 in Solid tumours
  • 26 Jan 2023 Centessa Pharmaceuticals plans a phase I/IIa trial for Solid tumours

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top